# Clinical Study of SL19+22 CAR-T Cells for Relapsed or Refractory Non-Hodgkin Lymphoma

> **NCT05206071** · NA · UNKNOWN · sponsor: **Hebei Senlang Biotechnology Inc., Ltd.** · enrollment: 100 (estimated)

## Conditions studied

- Non-hodgkin's Lymphoma

## Interventions

- **BIOLOGICAL:** CD19+22 CAR-T cells

## Key facts

- **NCT ID:** NCT05206071
- **Lead sponsor:** Hebei Senlang Biotechnology Inc., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-05-01
- **Primary completion:** 2023-12-31
- **Final completion:** 2023-12-31
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2022-01-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05206071

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05206071, "Clinical Study of SL19+22 CAR-T Cells for Relapsed or Refractory Non-Hodgkin Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05206071. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*